Drugs / IVIG-L
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00138697 | May 2001 → Dec 2004 | dysgammaglobulinemia | Prothya Biosolutions | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00151840 | Oct 2001 → Mar 2002 | autoimmune thrombocytopenic purpura | Prothya Biosolutions | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVIG-L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00151840 ↗ |
| Modality | Protein / enzyme biologic | “liquid intravenous immunoglobulin product” NCT00138697 ↗ |
| Route | Intravenous | “Human Normal Intravenous Immunoglobulin for Intravenous Use” NCT00138697 ↗ |